Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy.

CONCLUSIONS: Circulating T-cell immunosenescence is observed in up to 28% of aNSCLC patients and correlates with lack of benefit from ICI but not from PCT.
PMID: 32887723 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 3, 2020 Category: Cancer & Oncology Authors: Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks LEL, Planchard D, Remon J, Sangaletti S, Proto C, Garassino MC, Soria JC, Marabelle A, Voisin AL, Farhane S, Tags: Clin Cancer Res Source Type: research